|Bid||5.20 x 800|
|Ask||5.90 x 1000|
|Day's Range||4.88 - 5.48|
|52 Week Range||1.04 - 8.16|
|Beta (5Y Monthly)||2.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||Dec 11, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.13|
OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on cytokine-based intratumoral immunotherapies, today announced the publication of research demonstrating the ability of its lead candidate TAVO™ (tavokinogene telseplasmid), a DNA-based interleukin-12 (IL-12), to activate tumor antigen specific antitumor immunity in patients with triple negative breast cancer (TNBC) in the peer-reviewed medical journal Clinical Cancer Research, a journal of the American Association for Cancer Research. The manuscript by Melinda L. Telli, M.D. et al. is titled, "Intratumoral plasmid IL-12 expands CD8+ T cells and induces a CXCR3 gene signature in triple-negative breast tumors that sensitizes patients to anti-PD-1 therapy," and is available online.
OncoSec Medical Incorporated ("OncoSec") (Nasdaq:ONCS), a late-stage biotechnology company focused on designing, developing and commercializing innovative therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer, today announced the approval of $2.5 million in tax credit certificates from the New Jersey Economic Development Authority (NJEDA).
OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotech industry veteran with more than 15 years of experience, as Vice President of Clinical Development effective February 18, 2021.